Clever Leaves Teams Up With SOMAÍ Pharma., Completes First CBD Extract Shipments To Portugal

Clever Leaves Holdings Inc. CLVR CLVRW has entered into a five-year agreement with SOMAÍ Pharmaceuticals, to supply its operations in Portugal with EU-GMP certified CBD extracts from Colombia.

With the first shipments under the agreement already completed, Clever Leaves will continue to supply EU-GMP pharmaceutical-grade APIs and CBD extracts, produced in the company’s facility in Colombia, to SOMAÍ for further processing into finished products for patients across Europe. These are the first commercial shipments Clever Leaves has sent to Portugal, adding to the more than 15 countries that Clever Leaves has exported to from its European Union Good Manufacturing Practices certified facility in Colombia.

“By combining our expertise in producing and developing high-quality pharmaceutical-grade products with SOMAÍ's innovative approach to drug delivery systems, we aim to streamline patient access to pharmaceutical-grade cannabis products throughout Europe. This collaboration signifies Clever Leaves’ commitment to shaping the future of the global medical cannabis industry and grows our position in Europe's rapidly expanding medical cannabis market,” stated Andres Fajardo, CEO and co-founder of Clever Leaves.

Michael Sassano, CEO and founder of SOMAÍ Pharmaceuticals, stated “SOMAÍ Pharmaceuticals embarked on an extensive quest to seek a formidable partner to launch one of the most comprehensive cannabis product lines for the flourishing European markets. We are proud to be working with the highly professional Clever Leaves team and are most impressed with the high-quality EU-GMP CBD extract. We look forward to further collaborations with Clever Leaves to propel our product lines with even more advanced formulations and delivery methods.”

Photo: Benzinga edit with photos by geralt, lindsayfox on Pixabay

Related News

Clever Leaves' Q1 Net Loss Drops Significantly After Operating Expenses Slashed By 48%

Clever Leaves Teams Up With Hypera Pharma To Supply CBD-Dominant Oral Solutions For Brazilian Patients